Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pear Therapeutics Inc.

www.peartherapeutics.com

Latest From Pear Therapeutics Inc.

Pacts In Medtech: BI, Inflammasome Work On Retinal Disease; Takeda And Prometheus Take On IBD

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.

Pacts in Medtech Deals

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sales & Earnings Commercial

Sandoz Breaks Off Digital Deal With Pear

Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.

Strategy Digital Health
See All

Company Information

  • Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pear Therapeutics Inc.
  • Senior Management
  • Guiffre Christopher, CFO & CEO
    Alex Waldron, Chief Commercial Officer
    Ian McFarland, General Mgr. & CTO
    Yuri Maricich , MD, Acting CMO & Head, Clinical Dev.
  • Contact Info
  • Pear Therapeutics Inc.
    745 Atlantic Ave.
    Boston, MA 02111
    USA
UsernamePublicRestriction

Register